Is retatrutide approved for sleep apnea or knee arthritis?

No. Retatrutide is not approved for anything. Eli Lilly said in July 2026 that it plans to file a Biologics License Application in the first quarter of 2027, which puts the earliest realistic decision in late 2027 under priority review. Until then there is no approved indication for obesity, sleep apnea, or osteoarthritis.

What did TRIUMPH-4 show for knee osteoarthritis?

TRIUMPH-4 randomized 445 adults with obesity or overweight and knee osteoarthritis 1:1:1 to retatrutide 9 mg, retatrutide 12 mg, or placebo for 68 weeks. Weight fell 26.4% on 9 mg and 28.7% on 12 mg versus 2.1% on placebo. WOMAC pain scores fell 4.5 points on 9 mg and 4.4 points on 12 mg versus 2.4 points on placebo.

Is there already an approved drug for obesity-related sleep apnea?

Yes. The FDA approved Zepbound (tirzepatide) on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. It is the first prescription medication approved for OSA, and it is available now, unlike retatrutide.

Does losing weight cure sleep apnea?

Not reliably. Weight loss lowers the apnea-hypopnea index substantially for many people with obesity-related OSA, and some reach remission, but a large share still have measurable apnea afterward. In SURMOUNT-OSA, roughly 42% to 50% of treated participants reached remission or mild, non-symptomatic OSA at one year, which means most did not. Do not stop PAP therapy based on weight loss without a repeat sleep study.

Can Retatrutide Treat Sleep Apnea and Knee Osteoarthritis?

Q: How much did retatrutide reduce sleep apnea severity?

In the nested obstructive sleep apnea protocol reported in June 2026, retatrutide reduced the apnea-hypopnea index by up to 36.1 events per hour, a 60.6% reduction from a baseline of 58.6 events per hour, in participants with moderate-to-severe OSA at 80 weeks. That moves the average participant from severe territory into roughly the moderate range.

The short answer: yes, in trials, and no, not as an approved treatment. The TRIUMPH Phase 3 program tested retatrutide against two obesity complications head-on. In the nested obstructive sleep apnea protocol, it reduced the apnea-hypopnea index by up to 36.1 events per hour, a 60.6% cut from a baseline of 58.6. In the standalone knee osteoarthritis trial, TRIUMPH-4, it reduced WOMAC pain scores by up to 4.5 points alongside 28.7% weight loss. Retatrutide remains unapproved for any indication, so none of this is available by prescription today.

Why test these two conditions at all?

Because they are the complications that make obesity disabling rather than just measurable, and because the mechanism connecting them to body weight is mechanical and plausible.

In obstructive sleep apnea, fat deposition around the neck and tongue narrows the upper airway, and abdominal weight reduces lung volume, which makes the airway more collapsible during sleep. In knee osteoarthritis, load across the joint scales with body weight, and adipose tissue also drives systemic inflammation.

That is why Lilly built the TRIUMPH program around them rather than testing weight alone. The design paper describes four Phase 3 trials in more than 5,800 participants: TRIUMPH-1 and TRIUMPH-2 are weight-management basket trials with sleep apnea and osteoarthritis protocols nested inside them, TRIUMPH-3 studies people with established cardiovascular disease, and TRIUMPH-4 is a standalone knee osteoarthritis trial (Giblin et al., Diabetes, Obesity and Metabolism, 2026).

What did the sleep apnea data show?

Lilly reported the OSA results on June 6, 2026, and presented them at the American Diabetes Association scientific sessions.

In participants with moderate-to-severe OSA, retatrutide reduced the apnea-hypopnea index by up to 36.1 events per hour, a 60.6% reduction, from a baseline of 58.6 events per hour at 80 weeks (Eli Lilly, June 6, 2026).

Some translation. The apnea-hypopnea index counts breathing interruptions per hour of sleep. Five to 15 is mild, 15 to 30 is moderate, and above 30 is severe. A baseline of 58.6 is severe by a wide margin. Cutting 36.1 events per hour off that leaves an average around 22, which lands in the moderate band.

That is a large effect for a drug. It is also not a cure, and the distinction matters more here than in most places. An average participant improving from severe to moderate still has clinically significant sleep apnea, still fragments their sleep, and in most cases still needs treatment for it.

What did TRIUMPH-4 show for knees?

TRIUMPH-4 is the cleaner of the two datasets because it was a dedicated trial with pain as a co-primary endpoint rather than a nested protocol.

It randomized 445 adults with obesity or overweight plus knee osteoarthritis 1:1:1 to weekly retatrutide escalated to 9 mg, retatrutide escalated to 12 mg, or placebo, for 68 weeks of treatment plus 4 weeks of safety follow-up. The co-primary endpoints were percent change in body weight and change in the WOMAC pain subscale at week 68.

Results:

Body weight: −26.4% on 9 mg, −28.7% on 12 mg, −2.1% on placebo
WOMAC pain: −4.5 points on 9 mg, −4.4 points on 12 mg, −2.4 points on placebo

Lilly's December 2025 announcement framed the top-dose result as up to 71.2 lbs of weight loss with substantial relief from osteoarthritis pain, and reported that more than one in eight treated participants finished the trial free of knee pain.

Two honest caveats. First, the placebo group also improved by 2.4 points, which is the usual and large placebo response in pain trials; the drug effect is the difference, not the raw number. Second, 9 mg and 12 mg produced essentially the same pain result despite different weight loss, which suggests the benefit is not a simple linear function of pounds lost.

What about side effects in these populations?

The same profile as the rest of the class, at the same intensity you would expect at these doses. In TRIUMPH-4, nausea occurred in 38.1% to 43.2% of treated participants, diarrhea in 33.1% to 34.7%, and constipation in 21.8% to 25.0%. Discontinuation due to adverse events ran 12.2% to 18.2% on retatrutide versus 4.0% on placebo.

That discontinuation gap is worth sitting with. Roughly one in six or seven people at these doses stopped because of side effects. Our guide to retatrutide side effects covers the full profile.

Is there anything approved for this today?

Yes, for sleep apnea. The FDA approved Zepbound (tirzepatide) on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, the first prescription medicine approved for the condition (Eli Lilly, December 2024).

The SURMOUNT-OSA trials randomized 469 adults across two studies, one in people unable or unwilling to use positive airway pressure and one in people who stayed on PAP. At one year, roughly 42% of tirzepatide-treated participants without PAP and 50% with PAP reached remission or mild, non-symptomatic OSA, versus 16% and 14% on placebo.

Read that as the realistic ceiling. Even with an approved drug and substantial weight loss, about half did not reach remission. For knee osteoarthritis, nothing in this class is approved.

What this means if you have either condition

Do not wait for retatrutide. A filing is planned for the first quarter of 2027, which puts an approval decision in late 2027 at the earliest. Our tracker on when retatrutide may be FDA approved follows the timeline.
Do not stop PAP therapy because you are losing weight. Improvement is measured with a repeat sleep study, not with a scale.
Do not buy gray-market "research peptide" retatrutide to treat either condition. Those products sit outside the regulated supply chain, with no verification of identity, dose, purity, or sterility.
Do ask about approved options. For OSA with obesity, tirzepatide is available now. For knee osteoarthritis, weight loss by any means, plus strengthening exercise, remains the evidence-supported foundation.

The bottom line

Retatrutide produced large, real improvements in both conditions in Phase 3: a 60.6% cut in the apnea-hypopnea index and a 4.5-point drop in WOMAC knee pain. Neither result is an approval, neither is a cure, and the tolerability cost at 9 mg and 12 mg is not trivial. The useful conclusion is narrower than the headlines: treating obesity aggressively moves its complications, and the size of that movement is now measured rather than assumed. Our trial tracker follows each readout as it lands.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not approved or available by prescription.